|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ren SC, Chen R and Sun YH: Prostate cancer
research in China. Asian J Androl. 15:350–353. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shi Y, Lan F, Matson C, Mulligan P,
Whetstine JR, Cole PA, Casero RA and Shi Y: Histone demethylation
mediated by the nuclear amine oxidase homolog LSD1. Cell.
119:941–953. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Metzger E, Wissmann M, Yin N, Müller JM,
Schneider R, Peters AH, Günther T, Buettner R and Schüle R: LSD1
demeth-ylates repressive histone marks to promote androgen-receptor
dependent transcription. Nature. 437:436–439. 2005.PubMed/NCBI
|
|
5
|
Wissmann M, Yin N, Müller JM, Greschik H,
Fodor BD, Jenuwein T, Vogler C, Schneider R, Günther T, Buettner R,
et al: Cooperative demethylation by JMJD2C and LSD1 promotes
androgen receptor-dependent gene expression. Nat Cell Biol.
9:347–353. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Huang J, Sengupta R, Espejo AB, Lee MG,
Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT,
Jenuwein T, et al: p53 is regulated by the lysine demethylase LSD1.
Nature. 449:105–108. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scoumanne A and Chen X: The
lysine-specific demethylase 1 is required for cell proliferation in
both p53-dependent and -independent manners. J Biol Chem.
282:15471–15475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nagasawa S, Sedukhina AS, Nakagawa Y,
Maeda I, Kubota M, Ohnuma S, Tsugawa K, Ohta T, Roche-Molina M,
Bernal JA, et al: LSD1 overexpression is associated with poor
prognosis in basal-like breast cancer, and sensitivity to PARP
inhibition. PLoS One. 10:e01180022015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim S, Janzer A, Becker A, Zimmer A,
Schüle R, Buettner R and Kirfel J: Lysine-specific demethylase 1
(LSD1) is highly expressed in ER-negative breast cancers and a
biomarker predicting aggressive biology. Carcinogenesis.
31:512–520. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lv T, Yuan D, Miao X, Lv Y, Zhan P, Shen X
and Song Y: Overexpression of LSD1 promotes proliferation,
migration and invasion in non-small cell lung cancer. PLoS One.
7:e350652012. View Article : Google Scholar
|
|
11
|
Hayami S, Kelly JD, Cho HS, Yoshimatsu M,
Unoki M, Tsunoda T, Field HI, Neal DE, Yamaue H, Ponder BA, et al:
Overexpression of LSD1 contributes to human carcinogenesis through
chromatin regulation in various cancers. Int J Cancer. 128:574–586.
2011. View Article : Google Scholar
|
|
12
|
Kauffman EC, Robinson BD, Downes MJ,
Powell LG, Lee MM, Scherr DS, Gudas LJ and Mongan NP: Role of
androgen receptor and associated lysine-demethylase coregulators,
LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Mol Carcinog. 50:931–944. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Konovalov S and Garcia-Bassets I: Analysis
of the levels of lysine-specific demethylase 1 (LSD1) mRNA in human
ovarian tumors and the effects of chemical LSD1 inhibitors in
ovarian cancer cell lines. J Ovarian Res. 6:752013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Etani T, Suzuki T, Naiki T, Naiki-Ito A,
Ando R, Iida K, Kawai N, Tozawa K, Miyata N, Kohri K, et al: NCL1,
a highly selective lysine-specific demethylase 1 inhibitor,
suppresses prostate cancer without adverse effect. Oncotarget.
6:2865–2878. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kahl P, Gullotti L, Heukamp LC, Wolf S,
Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J,
Metzger E, et al: Androgen receptor coactivators lysine-specific
histone demethylase 1 and four and a half LIM domain protein 2
predict risk of prostate cancer recurrence. Cancer Res.
66:11341–11347. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu CY, Hsieh CY, Huang KE, Chang C and
Kang HY: Cryptotanshinone down-regulates androgen receptor
signaling by modulating lysine-specific demethylase 1 function. Int
J Cancer. 131:1423–1434. 2012. View Article : Google Scholar
|
|
17
|
Willmann D, Lim S, Wetzel S, Metzger E,
Jandausch A, Wilk W, Jung M, Forne I, Imhof A, Janzer A, et al:
Impairment of prostate cancer cell growth by a selective and
reversible lysine-specific demethylase 1 inhibitor. Int J Cancer.
131:2704–2709. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kashyap V, Ahmad S, Nilsson EM, Helczynski
L, Kenna S, Persson JL, Gudas LJ and Mongan NP: The lysine specific
demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate
cancer. Mol Oncol. 7:555–566. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ketscher A, Jilg CA, Willmann D, Hummel B,
Imhof A, Rüsseler V, Hölz S, Metzger E, Müller JM and Schüle R:
LSD1 controls metastasis of androgen-independent prostate cancer
cells through PXN and LPAR6. Oncogenesis. 3:e1202014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tamura K, Furihata M, Tsunoda T, Ashida S,
Takata R, Obara W, Yoshioka H, Daigo Y, Nasu Y, Kumon H, et al:
Molecular features of hormone-refractory prostate cancer cells by
genome-wide gene expression profiles. Cancer Res. 67:5117–5125.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Steinkamp MP, O'Mahony OA, Brogley M,
Rehman H, Lapensee EW, Dhanasekaran S, Hofer MD, Kuefer R,
Chinnaiyan A, Rubin MA, et al: Treatment-dependent androgen
receptor mutations in prostate cancer exploit multiple mechanisms
to evade therapy. Cancer Res. 69:4434–4442. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hu R, Dunn TA, Wei S, Isharwal S, Veltri
RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, et al:
Ligand-independent androgen receptor variants derived from splicing
of cryptic exons signify hormone-refractory prostate cancer. Cancer
Res. 69:16–22. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Harris WP, Mostaghel EA, Nelson PS and
Montgomery B: Androgen deprivation therapy: Progress in
understanding mechanisms of resistance and optimizing androgen
depletion. Nat Clin Pract Urol. 6:76–85. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rozan LM and El-Deiry WS: p53 downstream
target genes and tumor suppression: A classical view in evolution.
Cell Death Differ. 14:3–9. 2007. View Article : Google Scholar
|
|
25
|
Hollstein M, Sidransky D, Vogelstein B and
Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Qian J, Hirasawa K, Bostwick DG,
Bergstralh EJ, Slezak JM, Anderl KL, Borell TJ, Lieber MM and
Jenkins RB: Loss of p53 and c-myc overrepresentation in stage
T(2–3)N(1–3)M(0) prostate cancer are potential markers for cancer
progression. Mod Pathol. 15:35–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zegarra-Moro OL, Schmidt LJ, Huang H and
Tindall DJ: Disruption of androgen receptor function inhibits
proliferation of androgen-refractory prostate cancer cells. Cancer
Res. 62:1008–1013. 2002.PubMed/NCBI
|
|
28
|
Metzger E, Wissmann M and Schüle R:
Histone demethylation and androgen-dependent transcription. Curr
Opin Genet Dev. 16:513–517. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lu S, Tsai SY and Tsai MJ: Molecular
mechanisms of androgen-independent growth of human prostate cancer
LNCaP-AI cells. Endocrinology. 140:5054–5059. 1999.PubMed/NCBI
|
|
30
|
Berthois Y, Katzenellenbogen JA and
Katzenellenbogen BS: Phenol red in tissue culture media is a weak
estrogen: Implications concerning the study of estrogen-responsive
cells in culture. Proc Natl Acad Sci USA. 83:2496–2500. 1986.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Shen R, Dorai T, Szaboles M, Katz AE,
Olsson CA and Buttyan R: Transdifferentiation of cultured human
prostate cancer cells to a neuroendocrine cell phenotype in a
hormone-depleted medium. Urol Oncol. 3:67–75. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Burchardt T, Burchardt M, Chen MW, Cao Y,
de la Taille A, Shabsigh A, Hayek O, Dorai T and Buttyan R:
Transdifferentiation of prostate cancer cells to a neuroendocrine
cell phenotype in vitro and in vivo. J Urol. 162:1800–1805. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Deeble PD, Murphy DJ, Parsons SJ and Cox
ME: Interleukin-6- and cyclic AMP-mediated signaling potentiates
neuroendocrine differentiation of LNCaP prostate tumor cells. Mol
Cell Biol. 21:8471–8482. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Vashchenko N and Abrahamsson PA:
Neuroendocrine differentiation in prostate cancer: Implications for
new treatment modalities. Eur Urol. 47:147–155. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Balk SP and Knudsen KE: AR, the cell
cycle, and prostate cancer. Nucl Recept Signal.
6:e0012008.PubMed/NCBI
|
|
36
|
Ramamurthy VP, Ramalingam S, Gediya L,
Kwegyir-Afful AK and Njar VC: Simultaneous targeting of androgen
receptor (AR) and MAPK-interacting kinases (MNKs) by novel
retinamides inhibits growth of human prostate cancer cell lines.
Oncotarget. 6:3195–3210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kastan MB, Canman CE and Leonard CJ: P53,
cell cycle control and apoptosis: Implications for cancer. Cancer
Metastasis Rev. 14:3–15. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Enoch T and Norbury C: Cellular responses
to DNA damage: Cell-cycle checkpoints, apoptosis and the roles of
p53 and ATM. Trends Biochem Sci. 20:426–430. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fernald K and Kurokawa M: Evading
apoptosis in cancer. Trends Cell Biol. 23:620–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Yu J and Zhang L: The transcriptional
targets of p53 in apoptosis control. Biochem Biophys Res Commun.
331:851–858. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Galluzzi L, Morselli E, Kepp O, Tajeddine
N and Kroemer G: Targeting p53 to mitochondria for cancer therapy.
Cell Cycle. 7:1949–1955. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Agarwal ML, Taylor WR, Chernov MV,
Chernova OB and Stark GR: The p53 network. J Biol Chem. 273:1–4.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Vogelstein B, Lane D and Levine AJ:
Surfing the p53 network. Nature. 408:307–310. 2000. View Article : Google Scholar : PubMed/NCBI
|
